title: Building a hit list for the fight against metastatic castration resistant prostate cancer.
abstract: Identification of genetic alterations in Metastatic Castration Resistant Prostate Cancer (mCRPC) may provide scientists and clinicians with a list of new targets for drug research and development. Recently published in Cell, Robinson et al. present the first look at genetic data from mCRPC lesions gathered over multiple years and from many institutions.
authors.affiliation: a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Strope
authors.affiliation: a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Price
authors.affiliation: a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D020869:Gene Expression Profiling / Q000379:methods*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000235:genetics* / Q000473:pathology*
keywords: Actionable tumors; PTEN; androgen deprivation; androgen receptor; genetic alterations; mCRPC; translational medication
references.citation: Cell. 2015 May 21;161(5):1215-1228
references.pmid: 26000489
references.citation: Cell. 2007 Jan 12;128(1):129-39
references.pmid: 17218260
references.citation: N Engl J Med. 2014 Sep 11;371(11):1028-38
references.pmid: 25184630
references.citation: Cancer Cell. 2010 Jul 13;18(1):11-22
references.pmid: 20579941
references.citation: Science. 1997 Mar 28;275(5308):1943-7
references.pmid: 9072974